Current status and future perspectives of liquid biopsy in non-small cell lung cancer

With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blo...

Full description

Bibliographic Details
Main Authors:	Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
Format:	Article
Language:	English
Published:	Korean Society of Pathologists & the Korean Society for Cytopathology 2020-05-01
Series:	Journal of Pathology and Translational Medicine
Subjects:	carcinoma, non-small cell lung cancer liquid biopsy circulating tumor dna epidermal growth factor receptor biomarkers
Online Access:	http://www.jpatholtm.org/upload/pdf/jptm-2020-02-27.pdf

id	doaj-800bea470f654f8b97885b4fc2e0127c
record_format	Article
spelling	doaj-800bea470f654f8b97885b4fc2e0127c2020-11-25T03:08:25ZengKorean Society of Pathologists & the Korean Society for CytopathologyJournal of Pathology and Translational Medicine2383-78372383-78452020-05-0154320421210.4132/jptm.2020.02.2716901Current status and future perspectives of liquid biopsy in non-small cell lung cancerSunhee Chang0Jae Young Hur1Yoon-La Choi2Chang Hun Lee3Wan Seop Kim4 Department of Pathology, Inje University Ilsan Paik Hospital, Goyang, Korea Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Pathology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, KoreaWith advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practice in advanced NSCLC patients to guide tyrosine kinase inhibitor treatment. In the near future, liquid biopsy will be a crucial prognostic, predictive, and diagnostic method in NSCLC. Here we present the current status and future perspectives of liquid biopsy in NSCLC.http://www.jpatholtm.org/upload/pdf/jptm-2020-02-27.pdfcarcinoma, non-small cell lung cancerliquid biopsycirculating tumor dnaepidermal growth factor receptorbiomarkers
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Sunhee Chang Jae Young Hur Yoon-La Choi Chang Hun Lee Wan Seop Kim
spellingShingle	Sunhee Chang Jae Young Hur Yoon-La Choi Chang Hun Lee Wan Seop Kim Current status and future perspectives of liquid biopsy in non-small cell lung cancer Journal of Pathology and Translational Medicine carcinoma, non-small cell lung cancer liquid biopsy circulating tumor dna epidermal growth factor receptor biomarkers
author_facet	Sunhee Chang Jae Young Hur Yoon-La Choi Chang Hun Lee Wan Seop Kim
author_sort	Sunhee Chang
title	Current status and future perspectives of liquid biopsy in non-small cell lung cancer
title_short	Current status and future perspectives of liquid biopsy in non-small cell lung cancer
title_full	Current status and future perspectives of liquid biopsy in non-small cell lung cancer
title_fullStr	Current status and future perspectives of liquid biopsy in non-small cell lung cancer
title_full_unstemmed	Current status and future perspectives of liquid biopsy in non-small cell lung cancer
title_sort	current status and future perspectives of liquid biopsy in non-small cell lung cancer
publisher	Korean Society of Pathologists & the Korean Society for Cytopathology
series	Journal of Pathology and Translational Medicine
issn	2383-7837 2383-7845
publishDate	2020-05-01
description	With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practice in advanced NSCLC patients to guide tyrosine kinase inhibitor treatment. In the near future, liquid biopsy will be a crucial prognostic, predictive, and diagnostic method in NSCLC. Here we present the current status and future perspectives of liquid biopsy in NSCLC.
topic	carcinoma, non-small cell lung cancer liquid biopsy circulating tumor dna epidermal growth factor receptor biomarkers
url	http://www.jpatholtm.org/upload/pdf/jptm-2020-02-27.pdf
work_keys_str_mv	AT sunheechang currentstatusandfutureperspectivesofliquidbiopsyinnonsmallcelllungcancer AT jaeyounghur currentstatusandfutureperspectivesofliquidbiopsyinnonsmallcelllungcancer AT yoonlachoi currentstatusandfutureperspectivesofliquidbiopsyinnonsmallcelllungcancer AT changhunlee currentstatusandfutureperspectivesofliquidbiopsyinnonsmallcelllungcancer AT wanseopkim currentstatusandfutureperspectivesofliquidbiopsyinnonsmallcelllungcancer
_version_	1724666587678507008

Current status and future perspectives of liquid biopsy in non-small cell lung cancer

Similar Items